العربيةStart a conversationContact
Insights

Deal Brief · Healthcare & Life Sciences · 21 October 2026

The CCI cleared KKR's 100% buyout of Sahrudaya Health Care on 21 October 2026 without a price. Medicover's filings supply one: EUR 1.2 billion of enterprise value for about 4,800 beds, close to 46 times trailing EBITDA.

On 21 October 2026 the Competition Commission of India approved the acquisition of 100% of Sahrudaya Health Care Private Limited by Maybach Asia Holdings II Pte. Ltd., a vehicle owned by KKR-advised funds. The CCI describes 28 hospitals/units and about 4,800 beds across south and west India, and gives no price. Medicover, the Stockholm-listed controlling shareholder, priced it on 6 August: an enterprise value of EUR 1.2 billion, an equity purchase price of INR 105.0 billion paid in one instalment at closing, and EUR 0.1 billion of shareholder loans taken over by KKR, against indicative trailing EBITDA of EUR 26.1 million. The headline is enterprise value, the multiple is on capacity rather than current earnings, and the hospital count depends on whose document you read.

The 30-second read

What a board member needs before the next meeting on this.

  1. The EUR 1.2 billion is enterprise value. Medicover's presentation puts the equity purchase price at INR 105.0 billion, about EUR 0.95 billion, paid at closing in one instalment, with KKR also taking EUR 0.1 billion of Medicover loans. On our arithmetic about EUR 0.15 billion of the enterprise value is itemised in neither document.
  2. The multiple prices capacity, not current earnings. Indicative trailing EBITDA to 30 June 2026 was EUR 26.1 million at an 11.8% margin, and EBIT EUR 5.4 million. On our arithmetic the enterprise value is about 46 times that EBITDA and about EUR 250,000 per bed.
  3. Count beds, not hospitals. The CCI documents describe 28 hospitals/units. Medicover and KKR both say 24 hospitals. All three say about 4,800 beds.
  4. Conceded overlaps did not slow the Commission. The parties' summary names horizontal overlaps in five cities and a national transplant market. Combination C-2026/08/1456 was notified on 19 August 2026 and approved on 21 October 2026, 63 days on our count. The detailed order is still to come.
Applies to Promoters and controlling shareholders of multi-city hospital networks in India and the GCC weighing a listing against a sponsor sale, minority partners in those networks, and investors using the KKR-Sahrudaya price as a valuation benchmark

On 21 October 2026 the Competition Commission of India approved the acquisition of 100% of the equity share capital of Sahrudaya Health Care Private Limited by Maybach Asia Holdings II Pte. Ltd., a special purpose vehicle indirectly owned by funds, vehicles and accounts advised and managed by subsidiaries of KKR & Co. Inc. (CCI press release 70/2026-27).

The release gives no price. The seller had already published one. On 6 August, Stockholm-listed Medicover announced the sale of 100% of Medicover Hospitals India to KKR-managed funds at an enterprise value of EUR 1.2 billion (Medicover press release, 6 August 2026).

It is the same company: Medicover entered India in 2017 by buying 22% of Sahrudaya Healthcare Private Limited, then nine hospitals in Andhra Pradesh and Telangana (Medicover, 21 August 2017). The headline needs taking apart before anyone uses it as a benchmark.

From minority stake to sponsor buyoutAug 2017Medicover buys 22%of Sahrudaya:nine hospitalsDec 2024Medicover startsevaluating anIndia listing6 Aug 2026Sale to KKR fundsannounced atEUR 1.2bn EV21 Oct 2026CCI approvesC-2026/08/1456Q4 2026Expected closing
01

The EUR 1.2 billion is enterprise value, and the cheque for the shares is smaller

Medicover's investor presentation puts the purchase price for the equity at INR 105.0 billion, about EUR 0.95 billion at the EUR/INR rate of 110 the presentation uses, paid at closing in one instalment (Medicover webcast presentation, 6 August 2026). KKR separately takes over EUR 0.1 billion of Medicover loans including accrued interest.

On our arithmetic that leaves about EUR 0.15 billion of the enterprise value itemised in neither document. Medicover owns 66.1% and its local partners 33.9%, and Medicover expects gross cash proceeds of about EUR 0.74 billion (Medicover press release). Neither document discloses an earn-out, a deferred tranche or a rollover. Anyone quoting EUR 1.2 billion as the price of the equity is overstating it by about a quarter.

02

The multiple prices capacity, not current earnings

Medicover's indicative figures for the twelve months to 30 June 2026 give the India business revenue of EUR 220.5 million, EBITDA of EUR 26.1 million at an 11.8% margin, and EBIT of EUR 5.4 million at a 2.4% operating margin (Medicover press release). On our arithmetic EUR 1.2 billion is about 46 times that trailing EBITDA, about 5.4 times revenue, and about EUR 250,000 of enterprise value for each of roughly 4,800 beds.

Medicover labels its figures indicative and subject to deconsolidation adjustments, so the multiple is a neighbourhood, not a point. A promoter who reads this deal as "Indian hospital networks trade at 46 times" has drawn the wrong conclusion. On our read, KKR priced what those beds earn at maturity; the trailing margin is the starting line.

The alternative the price had to beat was a listing. Medicover had been evaluating an Indian IPO of the business since December 2024 and concluded the sale was the superior route (Medicover press release), describing it as value realised "with greater certainty than an IPO" (Medicover presentation).

Buying, selling or valuing a healthcare business? Talk to the principal who runs the deal. Discuss a transaction

03

Count beds, because the hospital count depends on who is counting

The CCI release and the parties' summary filed under Regulation 13(2) of the Combinations Regulations, 2024 describe 28 hospitals/units (CCI summary, C-2026/08/1456). Medicover's release counts 24 hospitals at the end of June 2026, with about 11,400 employees (Medicover press release), and KKR's announcement also says 24 (KKR, 6 August 2026).

All of them put beds at about 4,800. On our arithmetic a per-hospital value built from the CCI count comes out about one-seventh lower than one built from the seller's. Value the network per bed, and reconcile your own unit count before a merger filing does it for you.

04

The overlaps the parties conceded did not slow the Commission

The summary names horizontal overlaps between the parties in hospital services in Hyderabad (including Secunderabad), Mumbai (including Navi Mumbai), Nashik, Visakhapatnam and Bangalore, and a national market for quaternary care in kidney, liver and bone marrow transplants, alongside a vertical link to medical devices and a complementary link to health insurance (CCI summary).

The CCI register records the notice on 19 August 2026 and approval on 21 October 2026 (CCI register of Section 31 orders): 63 days on our count, filed 13 days after the deal was announced. The detailed order, which will carry the Commission's market-share reasoning, has not yet been published. On this one data point, a sponsor with existing hospitals in the target's cities faced a timetable item, not a deal risk.

05

For a gcc or Indian promoter, the lesson is about the exit route

Our judgement: a promoter of a ramping multi-city network now has a sponsor control bid, paid in cash at closing, as a credible comparator to a listing, and should run the two against each other as Medicover did from December 2024 to August 2026 rather than treating an IPO as the default.

Before your next meeting

Four questions before quoting the KKR-Sahrudaya price

  1. Have we rebuilt the price from the filings, starting at INR 105.0 billion for the equity and EUR 0.1 billion of shareholder loans, and do we know what the remaining gap to EUR 1.2 billion of enterprise value represents?
  2. On a per-bed basis and on trailing and forward EBITDA, where does our own network sit against roughly EUR 250,000 of enterprise value per bed and an 11.8% trailing margin?
  3. Does our hospital count match the definition a buyer would put in a CCI summary, or will our information memorandum and the merger filing disagree?
  4. If a listing is our default exit, have we priced a sponsor control sale for cash at closing against it, as Medicover did from December 2024?

Before quoting this deal to a board, rebuild it from the filings. Start from INR 105.0 billion for the equity, add the EUR 0.1 billion of loans, and find out what the rest of the EUR 1.2 billion represents.

Put your own network on a per-bed basis and on trailing and forward EBITDA, and reconcile your hospital count to the definition the parties will file in a CCI summary. If a listing is your default exit, price a control sale against it this quarter. That is the work our transactions and capital practice runs.

Subscribe

The UAE healthcare regulatory briefing

What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.

One email a fortnight. Unsubscribe from any of them.

Engagement · Limited mandates

Choosing who advises you is itself a strategic decision.

We take a limited number of mandates at any time. If you are working a decision that needs independent counsel, start with a conversation.